On Monday November 19th, LMC Manna Research’s own Type 1 Diabetes & Exercise study was published in Diabetes Care. The FIT Study is one of the most complex and impactful studies that LMC Manna Research’s own research team of endocrinologists, epidemiologists, and scientists have completed to date.
Two years ago, the LMC Manna Research team headed by Chief Medical Officer Dr. Ronnie Aronson and Senior Scientist Michael Riddell, set out to explore the observation that post-exercise hyperglycemia, following high-intensity interval training (HIIT) in patients with type 1 diabetes (T1D), is largely underrecognized by the clinical community and generally undertreated. The aim of this study was to compare four multipliers of an individual’s insulin correction factor (ICF) to treat post-HIIT hyperglycemia.
RESEARCH DESIGN AND METHODS The FIT study had a randomized, crossover design in physically active subjects with T1D (mean ± SD age 34.9 ± 10.1 years, BMI 25.5 ± 2.5 kg/m2, and HbA1c 7.2 ± 0.9%) using multiple daily injections. Following an 8-week optimization period, with 300 units/mL insulin glargine used as the basal insulin, subjects performed four weekly sessions of 25 min of HIIT. If hyperglycemia (>8.0 mmol/L) resulted, subjects received a bolus insulin correction 15 min post-HIIT, based on their own ICF, adjusted by one of four multipliers: 0, 50, 100, or 150%.
For the full article, click HERE